Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Jessica M ThanosCenter for Brain Immunology and Glia (BIG), Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0001-7984-5361
Olivia C CampbellCenter for Brain Immunology and Glia (BIG), Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA.
Nick R NataleCenter for Brain Immunology and Glia (BIG), Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0001-5677-0977
Ana Royo MarcoCenter for Brain Immunology and Glia (BIG), Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-2801-2746
Michael A PuchalskiCenter for Brain Immunology and Glia (BIG), Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA.
John R LukensCenter for Brain Immunology and Glia (BIG), Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-6795-0866
Funding
Global Biothreats Training ProgramT32AI055432 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI CRISS, ALISON K, PETRI, WILLIAM A · 2003 to 2022
$4.0M
Making a case for CASS4 in Alzheimer's diseaseR01AG087406 · NIA · UNIVERSITY OF VIRGINIA · PI John R Lukens · 2024 to 2026
$1.7M
CLEC7A in microglia biology and Alzheimer's diseaseRF1AG078684 · NIA · UNIVERSITY OF VIRGINIA · PI LUKENS, JOHN R · 2023 to 2023
$1.6M
Alzheimer's Disease Therapy via the MR Image-Guided Deletion of Microglial SHIP-1 with Focused UltrasoundR01AG086344 · NIA · UNIVERSITY OF VIRGINIA · PI John R Lukens, Richard J. Price · 2025 to 2026
$1.5M
Role of the SYK-CARD9 signaling axis in Alzheimer's diseaseR01AG071996 · NIA · UNIVERSITY OF VIRGINIA · PI LUKENS, JOHN R · 2024 to 2025
$1.1M
CLEC7A in microglia biology and Alzheimer's diseaseR01AG078684 · NIA · UNIVERSITY OF VIRGINIA · PI John R Lukens · 2026 to 2026
$552k
Mechanisms Mediating Repair of Stereocilia F-actin in Sensory Hair CellsF31DC017370 · NIDCD · UNIVERSITY OF VIRGINIA · PI WAGNER, ELIZABETH LEE · 2018 to 2021
$109k
Exploring the role of hyper-phagocytic microglia and SYK signaling in the aged hippocampus during COVID-19F31NS135897 · NINDS · UNIVERSITY OF VIRGINIA · PI Nick Natale · 2023 to 2026
$107k
Cure Alzheimer's Fund N/ANIA NIH HHS R01 AG071996NIA NIH HHS R01 AG078684NIA NIH HHS R01 AG086344NIA NIH HHS R01 AG087406NIDCD NIH HHS F31 DC017370NIH HHS F31NS135897NIH HHS R01AG071996NIH HHS R01AG086344NIH HHS R01AG087406NIH HHS RF1AG078684NIH HHS T32AI055432NINDS NIH HHS F31 NS135897Owen's Family Foundation N/AThe Harrison Family Foundation N/AThe Steven A Newman AD Award N/A
6 · The paper itself
Abstract
Genotoxic stress, which includes DNA damage and the mis-localization of DNA and RNA, is a defining feature of tauopathies, Alzheimer's disease, and several other neurodegenerative disorders. Recent findings indicate that activation of the innate immune system in response to genotoxic stress can drive harmful neuroinflammation, compromise neuronal integrity, and promote neurodegeneration. Multiple innate immune sensors of genotoxic stress have recently been discovered, but the contributions of many of these emerging nucleic acid-sensing pathways in neurodegenerative disease pathogenesis remain largely unexplored. Z-DNA binding protein 1 (ZBP1) is one such recently discovered genotoxic stress sensor that has been shown to incite various forms of cell death as well as proinflammatory cytokine production in response to left-handed Z conformations of DNA (Z-DNA) and RNA (Z-RNA). Here, we show that ZBP1 deletion provides protection against tau pathology and neuronal loss in the PS19 mouse model of tauopathy. Moreover, we find that this rescue of tauopathy seen with ZBP1 ablation is associated with dampened activation of microglia and astrocytes. These findings identify ZBP1 as a pivotal genotoxic stress sensor that drives tau pathology, gliosis, and neuronal loss in tauopathy. This work further suggests that targeting ZBP1 may offer a therapeutic strategy to treat tau-mediated neurodegenerative disease.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Genotoxic Stress Sensor ZBP1 Drives Tau Pathology. · full record | OpenQuestion